The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

German science and technology giant Merck announced on Monday that it is to acquire US biopharmaceutical outfit SpringWorks Therapeutics as it attempts to ramp up growth in the healthcare sector.